Full Press Release Details
SkinHealth Systems Reports First Quarter 2026 Financial Results
Long Beach, Calif., May 7, 2026 - SkinHealth Systems Inc. (NASDAQ SKIN) ("SkinHealth Systems" or the Company ), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2026 ("Q1 2026").
"First quarter results reflect the strength of the business. We delivered revenue within our guidance range, significantly outperformed on adjusted EBITDA, and continued to expand margins through disciplined execution.
While the market remains challenging and we are lowering our full-year revenue outlook, the fundamentals are intact. The installed base is growing, the brand is strong, and we are taking direct action to improve execution while continuing to invest in the capabilities and innovation that will drive long-term growth." said Pedro Malha, President and CEO of SkinHealth Systems.
Key Operational and Business Metrics
| Three Months Ended March 31, | |||||||||||
| Unaudited ($ in millions) (1) | 2026 | 2025 | |||||||||
| Delivery Systems net sales | $ | 18.5 | $ | 20.2 | |||||||
| Consumables net sales | 46.4 | 49.4 | |||||||||
| Total net sales | $ | 64.9 | $ | 69.6 | |||||||
| Gross profit | $ | 44.4 | $ | 48.6 | |||||||
| Gross margin | 68.5 | % | 69.8 | % | |||||||
| Adjusted gross profit (2) | $ | 46.9 | $ | 50.0 | |||||||
| Adjusted gross margin (2) | 72.2 | % | 71.9 | % | |||||||
| Operating expenses | $ | 46.2 | $ | 60.6 | |||||||
| Adjusted operating expenses (2) | $ | 38.4 | $ | 42.8 | |||||||
| Net loss | $ | (6.6) | $ | (10.1) | |||||||
| Net loss margin | (10.2) | % | (14.5) | % | |||||||
| Adjusted EBITDA (2) | $ | 8.5 | $ | 7.3 | |||||||
| Adjusted EBITDA margin (2) | 13.1 | % | 10.4 | % |
| Three Months Ended March 31, | |||||||||
| Unaudited | 2026 | 2025 | |||||||
| Total delivery systems sold | 746 | 862 | |||||||
| Active install base (3) | 36,419 | 35,014 |
__________________________
(1) Amounts may not sum due to rounding.
(2) See Non-GAAP Financial Measures below.
(3) Estimated number of delivery systems owned by providers that have purchased consumables in the trailing twelve-month period.
First Quarter Financial Highlights
Net sales were $64.9 million for the first quarter of 2026, a decrease of (6.7)%, compared to the prior year period ( Q1 2025 ), due to lower delivery systems and consumables net sales. The Company placed 746 delivery systems during Q1 2026, compared to 862 during Q1 2025.
Gross margin was 68.5% in Q1 2026, compared to 69.8% in Q1 2025. The decrease in gross margin was primarily due to higher amortization expense. Adjusted gross margin was relatively flat at 72.2% in Q1 2026 compared to 71.9% in Q1 2025.
Operating expenses were $46.2 million in Q1 2026, compared to $60.6 million in Q1 2025. Adjusted operating expenses were $38.4 million in Q1 2026, compared to $42.8 million in Q1 2025. The improvement in operating expenses and adjusted operating expenses was primarily due to lower personnel-related expenses and lower marketing-related spend.
Net loss was $(6.6) million in Q1 2026, compared to $(10.1) million in Q1 2025. The change compared to the prior year was primarily due to lower operational spend, partially offset by lower net sales.
Adjusted EBITDA was $8.5 million in Q1 2026, compared to $7.3 million in Q1 2025. The improvement in adjusted EBITDA was primarily due to lower operational spend, partially offset by lower net sales.
Revised 2026 Financial Guidance
| Second Quarter 2026 | |
| Net sales | $72 - $77 million |
| Adjusted EBITDA (1) | $11 - $13 million |
| Fiscal Year 2026 | |
| Net sales | $280 - $295 million |
| Adjusted EBITDA (1) | $35 - $45 million |
__________________________
(1) See Non-GAAP Financial Measures below.
Revised 2026 financial guidance
Reflects continued pressure on year over year device sales.
Presumes no further material deterioration in current general market conditions or other unforeseen circumstances beyond the Company's control, such as foreign currency exchange rates, tariffs, and trade restrictions.
Excludes any unannounced acquisitions, dispositions or financings.
Regional Operational and Business Metrics
| Three Months Ended March 31, | |||||||||||
| Unaudited ($ in millions) (1) (2) | 2026 | 2025 | |||||||||
| Delivery Systems net sales | |||||||||||
| Americas | $ | 12.0 | $ | 13.1 | |||||||
| Asia-Pacific ("APAC") | 2.1 | 2.0 | |||||||||
| Europe, the Middle East and Africa ("EMEA") | 4.4 | 5.1 | |||||||||
| Total Delivery Systems net sales | $ | 18.5 | $ | 20.2 | |||||||
| Consumables net sales | |||||||||||
| Americas | $ | 32.6 | $ | 33.1 | |||||||
| APAC | 4.5 | 6.4 | |||||||||
| EMEA | 9.3 | 9.9 | |||||||||
| Total Consumables net sales | $ | 46.4 | $ | 49.4 | |||||||
| Net sales | |||||||||||
| Americas | $ | 44.6 | $ | 46.3 | |||||||
| APAC | 6.6 | 8.3 | |||||||||
| EMEA | 13.7 | 15.0 | |||||||||
| Total net sales | $ | 64.9 | $ | 69.6 | |||||||
| Delivery Systems sold | |||||||||||
| Americas | 438 | 550 | |||||||||
| APAC | 118 | 98 | |||||||||
| EMEA | 190 | 214 | |||||||||
| Total Delivery Systems sold | 746 | 862 |
__________________________
(1) Amounts may not sum due to rounding.
(2) During the second quarter of 2025, the Company transitioned sales in the China market to a distributor partner, and as a result, the Company has discontinued direct sales to customers in China.
SkinHealth Systems will host a conference call on Thursday, May 7, 2026, at 4 30 p.m. ET to review its first quarter 2026 financial results. The call may be accessed via live webcast through the Events Presentations page on our Investor Relations website at www.skinhealthsystems.com. A recording of the call will become available on the site approximately three hours after its conclusion.
Non-GAAP Financial Measures
In addition to results determined in accordance with accounting principles generally accepted in the United States of America ( GAAP ), management utilizes certain non-GAAP financial measures such as adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EBITDA margin for purposes of evaluating ongoing operations and for internal planning and forecasting purposes.
Management believes that these non-GAAP financial measures, when reviewed collectively with the Company's GAAP financial information, provide useful supplemental information to investors in assessing the Company's operating performance. These non-GAAP financial measures should not be considered as an alternative to GAAP financial information or as an indication of operating performance or any other measure of performance derived in accordance with GAAP, and may not provide information that is directly comparable to that provided by other companies in its industry, as these other companies may calculate non-GAAP financial measures differently, particularly related to unusual items.
Adjusted gross profit is gross profit excluding the effects of depreciation expense, amortization expense, and share-based compensation expense and other long-term incentive compensation. Adjusted gross margin represents adjusted gross profit as a percentage of net sales.
Adjusted operating expenses is calculated as total operating expenses excluding the effects of depreciation expense amortization expense share-based compensation expense and other long-term incentive compensation litigation related costs Go-to-Market restructuring and severance, restructuring, and other.
Adjusted EBITDA is calculated as net loss excluding the effects of (benefit) expense for income taxes depreciation expense amortization expense share-based compensation expense and other long-term incentive compensation interest expense interest income other income, net change in fair value of warrant liabilities foreign currency loss (gain), net litigation related costs Go-to-Market restructuring and severance, restructuring and other. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of net sales.
The Company does not provide a reconciliation of its fiscal 2026 adjusted EBITDA guidance to net loss, the most directly comparable forward looking GAAP financial measures, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, which cannot be done without unreasonable efforts, including adjustments that could be made for changes in fair value of warrant liabilities, integration and acquisition-related expenses, amortization expenses, non-cash share-based compensation, gains losses on foreign currency, and other charges reflected in our reconciliation of historic numbers, the amount of which, based on historical experience, could be significant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's fiscal 2026 adjusted EBITDA guidance is merely an outlook and is not a guarantee of future performance. Stockholders should not rely or place an undue reliance on such forward-looking statements. See "Forward-Looking Statements" for additional information.
SkinHealth Systems Inc.
Condensed Consolidated Statements of Comprehensive Income (Loss) (1)
($ in millions, except share and per share amounts)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Net sales | $ | 64.9 | $ | 69.6 | |||||||
| Cost of sales | 20.5 | 21.0 | |||||||||
| Gross profit | 44.4 | 48.6 | |||||||||
| Operating expenses | |||||||||||
| Selling and marketing | 23.2 | 26.0 | |||||||||
| Research and development | 1.1 | 1.0 | |||||||||
| General and administrative | 21.9 | 33.6 | |||||||||
| Total operating expenses | 46.2 | 60.6 | |||||||||
| Loss from operations | (1.8) | (12.0) | |||||||||
| Interest expense | 6.3 | 2.5 | |||||||||
| Interest income | (1.5) | (3.0) | |||||||||
| Other income, net | (1.0) | (0.1) | |||||||||
| Change in fair value of warrant liabilities | - | (0.3) | |||||||||
| Foreign currency transaction loss (gain), net | 1.2 | (1.9) | |||||||||
| Loss before provision for income taxes | (6.8) | (9.2) | |||||||||
| Income tax (benefit) expense | (0.2) | 0.9 | |||||||||
| Net loss | (6.6) | (10.1) | |||||||||
| Comprehensive loss, net of tax | |||||||||||
| Foreign currency translation adjustments | (0.3) | 1.1 | |||||||||
| Comprehensive loss | $ | (6.9) | $ | (9.0) | |||||||
| Net loss per share | |||||||||||
| Basic | $ | (0.05) | $ | (0.08) | |||||||
| Diluted | $ | (0.05) | $ | (0.08) | |||||||
| Weighted average common shares outstanding | |||||||||||
| Basic | 127,792,611 | 125,079,470 | |||||||||
| Diluted | 131,399,898 | 125,079,470 |
__________________________
(1)Amounts may not sum due to rounding.
SkinHealth Systems Inc.
Condensed Consolidated Balance Sheets (1)
| March 31, 2026 | December 31, 2025 | ||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash, cash equivalents, and restricted cash | $ | 204.4 | $ | 232.7 | |||
| Accounts receivable, net | 18.6 | 21.7 | |||||
| Inventories | 47.7 | 48.0 | |||||
| Income tax receivable | 1.6 | 1.7 | |||||
| Prepaid expenses and other current assets | 5.4 | 5.4 | |||||
| Total current assets | 277.7 | 309.5 | |||||
| Property and equipment, net | 2.3 | 2.5 | |||||
| Right-of-use assets, net | 20.3 | 11.6 | |||||
| Intangible assets, net | 32.8 | 35.8 | |||||
| Goodwill | 126.2 | 126.6 | |||||
| Deferred income tax assets, net | 2.4 | 1.9 | |||||
| Other assets | 11.5 | 11.9 | |||||
| TOTAL ASSETS | $ | 473.2 | $ | 499.8 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities | |||||||
| Current portion of convertible senior notes, net | $ | 102.9 | $ | 124.0 | |||
| Accounts payable | 15.9 | 15.6 | |||||
| Accrued payroll-related expenses | 13.0 | 24.9 | |||||
| Lease liabilities, current | 4.2 | 5.1 | |||||
| Income tax payable | 0.5 | 1.2 | |||||
| Other accrued expenses | 18.7 | 15.4 | |||||
| Total current liabilities | 155.2 | 186.3 | |||||
| Lease liabilities, non-current | 18.8 | 9.2 | |||||
| Deferred income tax liabilities, net | 0.4 | 0.4 | |||||
| Convertible senior notes, net | 241.3 | 240.4 | |||||
| Other long-term liabilities | 2.4 | 2.4 | |||||
| TOTAL LIABILITIES | $ | 418.0 | $ | 438.7 | |||
| Stockholders' equity | |||||||
| Class A Common Stock | $ | - | $ | - | |||
| Additional paid-in capital | 581.1 | 580.0 | |||||
| Accumulated other comprehensive loss | (1.7) | (1.4) | |||||
| Accumulated deficit | (524.1) | (517.5) | |||||
| Total stockholders' equity | $ | 55.2 | $ | 61.1 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 473.2 | $ | 499.8 |
__________________________
(1)Amounts may not sum due to rounding.
SkinHealth Systems Inc.
Condensed Consolidated Statement of Cash Flows (1)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Cash, cash equivalents, and restricted cash at beginning of period | $ | 232.7 | $ | 370.1 | ||||
| Operating activities | ||||||||
| Net loss | (6.6) | (10.1) | ||||||
| Non-cash adjustments | 10.2 | 10.2 | ||||||
| Change in operating assets and liabilities | ||||||||
| Accounts receivable | 2.5 | 4.0 | ||||||
| Inventories | (0.1) | 3.8 | ||||||
| Prepaid expenses, other current assets, and income tax receivable | - | 2.9 | ||||||
| Accounts payable, accrued expenses, and income tax payable | (9.6) | (5.7) | ||||||
| Other, net | (2.0) | (2.0) | ||||||
| Net cash (used for) provided by operating activities | (5.6) | 3.0 | ||||||
| Net cash used for investing activities | (1.6) | (1.1) | ||||||
| Net cash used for financing activities | (20.9) | (0.3) | ||||||
| Net change in cash, cash equivalents, and restricted cash | (28.1) | 1.6 | ||||||
| Effect of foreign currency translation | (0.2) | 1.4 | ||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 204.4 | $ | 373.0 |
__________________________
(1)Amounts may not sum due to rounding.
The following table reconciles gross profit to adjusted gross profit for the periods presented
| Three Months Ended March 31, | |||||||||||
| Unaudited ($ in millions) (1) | 2026 | 2025 | |||||||||
| Net sales | $ | 64.9 | $ | 69.6 | |||||||
| Gross profit | $ | 44.4 | $ | 48.6 | |||||||
| Gross margin | 68.5 | % | 69.8 | % | |||||||
| Adjusted to exclude the following | |||||||||||
| Depreciation expense | 0.2 | 0.2 | |||||||||
| Amortization expense | 2.1 | 1.1 | |||||||||
| Share-based compensation expense and other long-term incentive compensation (2) | 0.1 | 0.2 | |||||||||
| Adjusted gross profit | $ | 46.9 | $ | 50.0 | |||||||
| Adjusted gross margin | 72.2 | % | 71.9 | % |
__________________________
(1)Amounts may not sum due to rounding.
(2)Includes expense associated with long-term cash performance awards.
The following table reconciles total operating expenses to adjusted operating expenses for the periods presented
| Three Months Ended March 31, | |||||||||||
| Unaudited ($ in millions) (1) | 2026 | 2025 | |||||||||
| Total operating expenses | $ | 46.2 | $ | 60.6 | |||||||
| Adjusted to exclude the following | |||||||||||
| Depreciation expense | 0.4 | 1.6 | |||||||||
| Amortization expense | 2.7 | 3.2 | |||||||||
| Share-based compensation expense and other long-term incentive compensation (2) | 2.0 | 3.3 | |||||||||
| Litigation related costs | 2.2 | 6.9 | |||||||||
| Go-to-Market restructuring | 0.2 | 2.7 | |||||||||
| Severance, restructuring and other | 0.5 | - | |||||||||
| Adjusted operating expenses | $ | 38.4 | $ | 42.8 |
__________________________
(1)Amounts may not sum due to rounding.
(2)Includes expense associated with long-term cash performance awards that can be settled in either cash or Common Stock.
The following table reconciles net loss to adjusted EBITDA for the periods presented
| Three Months Ended March 31, | |||||||||||
| Unaudited ($ in millions) (1) | 2026 | 2025 | |||||||||
| Net sales | $ | 64.9 | $ | 69.6 | |||||||
| Net loss | $ | (6.6) | $ | (10.1) | |||||||
| Net loss margin | (10.2) | % | (14.5) | % | |||||||
| Adjusted to exclude the following | |||||||||||
| (Benefit) expense for income taxes | (0.2) | 0.9 | |||||||||
| Depreciation expense | 0.6 | 1.9 | |||||||||
| Amortization expense | 4.8 | 4.3 | |||||||||
| Share-based compensation expense and other long-term incentive compensation (2) | 2.1 | 3.5 | |||||||||
| Interest expense | 6.3 | 2.5 | |||||||||
| Interest income | (1.5) | (3.0) | |||||||||
| Other income, net | (1.0) | (0.1) | |||||||||
| Change in fair value of warrant liabilities | - | (0.3) | |||||||||
| Foreign currency loss (gain), net | 1.2 | (1.9) | |||||||||
| Litigation related costs | 2.2 | 6.9 | |||||||||
| Go-to-Market restructuring | 0.2 | 2.7 | |||||||||
| Severance, restructuring and other | 0.5 | - | |||||||||
| Adjusted EBITDA | $ | 8.5 | $ | 7.3 | |||||||
| Adjusted EBITDA margin | 13.1 | % | 10.4 | % |
__________________________
(1)Amounts may not sum due to rounding.
(2)Includes expense associated with long-term cash performance awards that can be settled in either cash or Common Stock.
About SkinHealth Systems
Forward-Looking Statements
Certain statements made in this release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding SkinHealth Systems Inc.'s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside SkinHealth Systems Inc.'s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Important factors that may affect actual results or outcomes include, among others SkinHealth Systems Inc.'s ability to manage growth SkinHealth Systems Inc.'s ability to execute its business plan potential negative reactions or outcomes related to the Company's name change in general and focused shift in operations potential litigation involving SkinHealth Systems Inc. changes in applicable laws or regulations the possibility that SkinHealth Systems Inc. may be adversely affected by other economic, business, and or competitive factors and other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the "SEC") and in the Company's subsequent filings with the SEC such as on a Quarterly Report on Form 10-Q. Those risks continue to be relevant to the Company's performance and financial condition. Moreover, the Company operates in a very competitive and rapidly changing environment. New risk factors emerge from time-to-time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. SkinHealth Systems Inc. expressly disclaims any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise.
Press press skinhealthsystems.com
Investors IR skinhealthsystems.com